Nicolas Llosa
Experienced in Graft Versus Host Disease (GvHD)

Dr. Nicolas Llosa

Oncology
Johns Hopkins Medicine
Johns Hopkins Children's Center
1800 Orleans Street, Bloomberg 11N, Bloomberg 11N, 
Baltimore, MD 
21 Years of Experience

Experienced in Graft Versus Host Disease (GvHD)
Johns Hopkins Medicine
Johns Hopkins Children's Center
1800 Orleans Street, Bloomberg 11N, Bloomberg 11N, 
Baltimore, MD 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

As instructor of oncology and pediatrics, Llosa’s research focus is the immunotherapy of sarcomas. My research focuses on understanding how the immune system interacts with cancer cells from sarcoma tumors. Sarcoma is a type of cancer that can occur in various locations in the body. Sarcoma is the general term for a broad group of cancers that includes tumors that form in the bones and in the soft (also called connective) tissues. Sarcomas affect people of all ages and some, such as Rhabdomyosarcoma, Neuroblastoma, Ewings sarcoma and Osteosarcoma, are more common in children and young adults. Treatments for sarcoma vary depending on tumor type, location and other factors. I concentrate in the immunotherapy of sarcomas. Immunotherapy (also called biologic therapy or biotherapy) is a type of cancer treatment designed to boost the body's natural defenses to fight the cancer. It uses materials either made by the body or in a laboratory to improve, target, or restore immune system function. Immunotherapy works by stopping or slowing the growth of cancer cells, stopping cancer from spreading to other parts of the body, or helping the immune system increase its effectiveness at eliminating cancer cells. There are several types of immunotherapy, including monoclonal antibodies, non-specific immunotherapies, and cancer vaccines. My specific area of interest is the use of drugs that target immune system checkpoints. The immune system has checkpoints to keep itself from attacking other normal cells in the body. Cancer cells sometimes take advantage of these checkpoints to avoid being attacked by the immune system. CTLA-4 and PD-1/PD-L1 are checkpoint molecules found on immune system cells (T cells) that can be blocked with drugs leading to a general raise in the immune system of the patients which helps it attack cancer cells. These types of drugs are currently being given to patients with melanoma (skin cancer), lung cancer and kidney cancer with great success and they have been found to shrink advanced tumors in many people. The best part of the treatment is that many of these tumor responses have been long-lasting so far, and the side effects are generally less serious than when using chemotherapy. Larger clinical trials are now studying both drugs, both alone and/or in combination with other treatments. My task is and will continue to be using the same type of approach for attacking sarcomas and hopefully obtained the very promising results and long lasting responses observed with the use of immune checkpoint inhibitors in other types of cancer.

Dr. Llosa is rated as an Experienced provider by MediFind in the treatment of Graft Versus Host Disease (GvHD). His top areas of expertise are Adult Soft Tissue Sarcoma, Osteosarcoma, Malignant Peripheral Nerve Sheath Tumor, Rhabdomyosarcoma, and Bone Marrow Transplant.

His clinical research consists of co-authoring 43 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 5 articles in the study of Graft Versus Host Disease (GvHD).

Residency
Tufts Medical Center, Pediatrics, 2009
Specialties
Oncology
Licenses
Pediatrics in MA
Board Certifications
American Board Of Pediatrics
Fellowships
Johns Hopkins University School of Medicine, Pediatric Oncology, 2014
National Institutes of Health Clinical Center, Pediatric Oncology, 2014
Languages Spoken
English
Spanish
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
First Health
  • INSURANCE PLAN
  • MEDICARE PDP
  • PPO
Geisinger
  • HMO
  • POS
  • PPO
Johns Hopkins Healthcare
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE-MEDICAID PLAN
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
View 2 Less Insurance Carriers -

Locations

Johns Hopkins Children's Center
1800 Orleans Street, Bloomberg 11N, Bloomberg 11N, Baltimore, MD 21287
Call: 410-955-8751

Additional Areas of Focus

Dr. Llosa has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Immune Thrombocytopenic Purpura (ITP)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


2 Clinical Trials

A Phase Ib/II Study to Evaluate the Safety, Feasibility and Efficacy of Nivolumab or Nivolumab in Combination With Azacitidine in Patients With Recurrent, Resectable Osteosarcoma
A Phase Ib/II Study to Evaluate the Safety, Feasibility and Efficacy of Nivolumab or Nivolumab in Combination With Azacitidine in Patients With Recurrent, Resectable Osteosarcoma
Enrollment Status: Active_not_recruiting
Publish Date: February 05, 2026
Intervention Type: Drug, Procedure
Study Drugs: Nivolumab, Azacitidine
Study Phase: Phase 1
Randomized Phase 3 Trial Evaluating the Addition of the IGF-1R Monoclonal Antibody Ganitumab (AMG 479, NSC# 750008) to Multiagent Chemotherapy for Patients With Newly Diagnosed Metastatic Ewing Sarcoma
Randomized Phase 3 Trial Evaluating the Addition of the IGF-1R Monoclonal Antibody Ganitumab (AMG 479, NSC# 750008) to Multiagent Chemotherapy for Patients With Newly Diagnosed Metastatic Ewing Sarcoma
Enrollment Status: Active_not_recruiting
Publish Date: December 01, 2025
Intervention Type: Drug, Procedure, Biological, Radiation
Study Drugs: Cyclophosphamide, Doxorubicin, Doxorubicin Hydrochloride, Etoposide, Etoposide Phosphate, Ganitumab, Ifosfamide, Vincristine, Vincristine Sulfate
Study Phase: Phase 3
View 1 Less Clinical Trial

42 Total Publications

Correction: Nivolumab and Relatlimab for the Treatment of Patients with Unresectable or Metastatic Mismatch Repair-Proficient Colorectal Cancer.
Correction: Nivolumab and Relatlimab for the Treatment of Patients with Unresectable or Metastatic Mismatch Repair-Proficient Colorectal Cancer.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: October 27, 2025
View All 42 Publications
Similar Doctors
Distinguished in Graft Versus Host Disease (GvHD)
Dr. Jean A. Yared
Hematology Oncology | Hematology | Oncology
Distinguished in Graft Versus Host Disease (GvHD)
Dr. Jean A. Yared
Hematology Oncology | Hematology | Oncology

University Of Maryland Oncology Associates PA

22 S Green St, 
Baltimore, MD 
 (1.7 miles away)
410-328-1230
Languages Spoken:
English, Arabic, French
See accepted insurances
Accepting New Patients

Jean Yared is a Hematologist Oncology specialist and a Hematologist in Baltimore, Maryland. Dr. Yared is rated as a Distinguished provider by MediFind in the treatment of Graft Versus Host Disease (GvHD). His top areas of expertise are Graft Versus Host Disease (GvHD), Acute Myeloid Leukemia (AML), Multiple Myeloma, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Yared is currently accepting new patients.

Distinguished in Graft Versus Host Disease (GvHD)
Dr. Scott Rowley
Oncology | Hematology
Distinguished in Graft Versus Host Disease (GvHD)
Dr. Scott Rowley
Oncology | Hematology
3800 Reservoir Rd NW, 
Washington, DC 
 (37.0 miles away)
202-444-3736
Languages Spoken:
English
See accepted insurances

Scott Rowley is an Oncologist and a Hematologist in Washington, Washington, D.c.. Dr. Rowley is rated as an Elite provider by MediFind in the treatment of Graft Versus Host Disease (GvHD). His top areas of expertise are Multiple Myeloma, Acute Myeloid Leukemia (AML), Acute Myeloblastic Leukemia without Maturation, Bone Marrow Transplant, and Colonoscopy.

Amy Dezern
Distinguished in Graft Versus Host Disease (GvHD)
Dr. Amy Dezern
Oncology | Hematology
Distinguished in Graft Versus Host Disease (GvHD)
Dr. Amy Dezern
Oncology | Hematology

Sidney Kimmel Comprehensive Cancer Center

401 North Broadway Street, Weinberg BLDG, Weinberg BLDG, 
Baltimore, MD 
 (1.0 miles away)
410-955-8964
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Dr. DeZern is a Professor of Oncology and Medicine at The Johns Hopkins University School of Medicine. She is active in the Division of Hematology Malignancies, Leukemia Program at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. Dr. DeZern has expertise in aplastic anemia, myelodysplastic syndromes, paroxysmal nocturnal hemoglobinuria, acute myeloid leukemia, and bone marrow transplantation. Dr. DeZern received her medical degree at The Johns Hopkins University School of Medicine. She completed a residency in internal medicine at Johns Hopkins, followed by fellowships in medical oncology and hematology, as well as obtained a Masters in Clinical Investigations at the Bloomberg School of Public health. Dr. DeZern is a member of the American Society of Hematology, the American Society of Clinical Oncology, and the American Society for Transplantation and Cellular Therapy. Dr. DeZern’s principle research activities consist of designing and conducting clinical trials that test investigational new therapies and approaches in the treatment of bone marrow failure (aplastic anemia and myelodysplastic syndromes). She has specific expertise in the use of alternative donor bone marrow transplantation in patients with severe aplastic anemia and trials of novel therapeutics for patients with myelodysplastic syndromes. Additionally, she has taken a rigorous approach to the study of diagnostics and supportive case (such as transfusion practices) in these patient populations. She is or has been the Principal Investigator for a number of multicenter trials in collaboration with the MDS Clinical Research Consortium, the Eastern Co-operative Oncology Group (ECOG)-ACRIN and now the Bone Marrow Trials Clinical Trials Network (BMTCTN). She is the Study Chair for the multi-site BMTCTN study (CHAMP) investigating the role of haploidentical donor transplantation using post-transplantation cyclophosphamide in patients with relapsed several aplastic anemia. Dr. DeZern is the local PI as well as the Deputy Chair for The National MDS Study, a collaborative natural history study of the NHLBI and the NCI. As a clinical investigator with a focus on translation of novel treatments to the clinic, Dr. DeZern’s goal is to improve outcomes for patients with bone marrow failure at the bedside and in her research environment. Dr. Dezern is rated as an Elite provider by MediFind in the treatment of Graft Versus Host Disease (GvHD). Her top areas of expertise are Myelodysplastic Syndrome (MDS), Acute Myeloid Leukemia (AML), Chronic Myelomonocytic Leukemia (CMML), Bone Marrow Transplant, and Bone Marrow Aspiration.

VIEW MORE GRAFT VERSUS HOST DISEASE (GVHD) DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Llosa's expertise for a condition
ConditionClose
      • Advanced
      • Adult Soft Tissue Sarcoma
        Dr. Llosa is
        Advanced
        . Learn about Adult Soft Tissue Sarcoma.
        See more Adult Soft Tissue Sarcoma experts
      • Ewing Sarcoma
        Dr. Llosa is
        Advanced
        . Learn about Ewing Sarcoma.
        See more Ewing Sarcoma experts
      • Malignant Peripheral Nerve Sheath Tumor
        Dr. Llosa is
        Advanced
        . Learn about Malignant Peripheral Nerve Sheath Tumor.
        See more Malignant Peripheral Nerve Sheath Tumor experts
      • Osteosarcoma
        Dr. Llosa is
        Advanced
        . Learn about Osteosarcoma.
        See more Osteosarcoma experts
      • Rhabdomyosarcoma
        Dr. Llosa is
        Advanced
        . Learn about Rhabdomyosarcoma.
        See more Rhabdomyosarcoma experts
      • Experienced
      • Bone Marrow Transplant
        Dr. Llosa is
        Experienced
        . Learn about Bone Marrow Transplant.
        See more Bone Marrow Transplant experts
      • Graft Versus Host Disease (GvHD)
        Dr. Llosa is
        Experienced
        . Learn about Graft Versus Host Disease (GvHD).
        See more Graft Versus Host Disease (GvHD) experts
      • Neurofibromatosis Type 1 (NF1)
        Dr. Llosa is
        Experienced
        . Learn about Neurofibromatosis Type 1 (NF1).
        See more Neurofibromatosis Type 1 (NF1) experts
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile
      For Patients
      • Our Story
      • How MediFind Works
      • Conditions A-Z
      • Doctor Directory
      • Symptoms Directory
      • Procedures Directory
      • Treatment Directory
      • Drug Directory
      • Infusion Center Finder
      • FAQ
      • Contact Us
      For Providers and Practices
      • Claim Your Profile
      • Newsroom
      Business Solutions
      • Provider
      • Network Solutions
      Additional Resources
      • Consumer Health Data Privacy Policy
      • Privacy Policy
      • Terms of Use
      • Advertising Policy
      • Content Policy
      Subscribe to our newsletter

      Sign up to stay informed about MediFind and get wellness sent your way.

      Close

        By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

        Bullet PinMediFind
        Follow us on
        This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
        © 2026 All Rights Reserved

        Request an Appointment

        If you are experiencing a medical emergency, call 9-1-1.

        MediFind will contact the provider for your appointment request. You’ll receive status updates by email. Your provider or MediFind will reach out to you directly by phone or email to schedule your appointment or request additional information.

        Patient Details

        This information is for the patient who will be seen at the appointment.

          Close

          Returning patient? Use your address on file with the provider.

          Insurance Details

          Please provide information of the primary insurance holder as the practice may require this information to schedule.

          Insurance Provider *
          Insurance ProviderClose

          Appointments Details

          Let’s get more information about your appointment.

                  0 / 1000
                  0 / 1000
                  By pressing the Submit button you are agreeing to MediFind’s Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.